Loading
A phase 1/2 trial of Pembrolizumab in melanoma and uveal melanoma, run by Ascentage Pharma Group Inc., active and no longer recruiting.
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03611868 by Ascentage Pharma Group Inc., with 230 participants planned, started 2018-08-29 and due to reach its primary completion in 2025-12-30. Interventions recorded: Phase 1b: APG-115+pembrolizumab. Conditions listed: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation. No results are recorded here; the registry entry is the source.
Shares Uveal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Uveal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab.